Navigation Links
Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis

INDIANAPOLIS, Feb. 26 /PRNewswire-USNewswire/ -- America's pharmaceutical research and biotechnology companies are testing a record number of potential medicines to treat two of the country's top killers. According to the latest report by the Pharmaceutical Research and Manufacturers of America (PhRMA) on medicines in the research pipeline, over 300 new medicines are in development to treat heart disease and stroke.

"This report reflects the never-ending commitment of our scientists and companies to improve healthcare by fighting debilitating chronic diseases, which often have devastating impacts on patients, their families and the American economy," said PhRMA Senior Vice President Ken Johnson at today's press conference. "This report also illustrates why the U.S. leads the world in discovering and developing new medicines."

More research and development of new medicines takes place in the U.S. than in any other country. Indiana has a fair share of that, with more than 6 percent of the nation's pharmaceuticals workforce employed in the Hoosier state. At least 10 pharmaceutical companies are headquartered in Indiana, and at least 13 additional companies maintain a division, branch or manufacturing plant in Indiana. National Institutes of Health funding for Indiana's biosciences has grown nearly twice the national rate over the past six years. The biopharmaceutical research industry contributes significantly to the state's economy.

The 312 heart and stroke medicines now being developed, more than double the number (146) under development in 2005. Innovative potential heart and stroke medicines - five being developed here in Indiana - hold particular relevance to Hoosiers because cardiovascular disease and stroke are the leading causes of death in the state. Indiana also ranks high for many factors that increase the risk of developing cardiovascular disease, including higher-than-national rates for smoking, high blood pressure, high cholesterol, and diabetes.

Today's news briefing featured Olympic gold medalist swimmer and Indiana University alum Mark Spitz, who suffers from high cholesterol. Considered one of the most dominant Olympic athletes ever, Spitz earned a total of 11 medals, including a record-breaking seven Gold Medals at the 1972 Munich Olympics. Spitz spoke of discovering, at age 38, that he had high cholesterol and was at risk for developing heart disease. Now, Spitz is an advocate for cholesterol testing and heart health, spurred by his personal battle.

"I realized that I had to get the message out that regardless of how healthy you think you are, you may be walking around with this silent killer. I was surprised that this could happen to me - after all, I've worked out my whole life. But heart disease and stroke can strike anyone," said Spitz.

The medicines in the report are being tested in human clinical trials or are awaiting approval by the U.S. Food and Drug Administration.

"In recent years, the development of effective medicines that control blood pressure and cholesterol has allowed us to better control the risk factors for cardiovascular events and has helped significantly cut deaths from heart disease and stroke," said Dr. J. Anthony Ware, Eli Lilly & Company, Vice President and Global Platform Leader, Diabetes and Cardiovascular.

According to a 2008 report by the American Heart Association, death rates for cardiovascular disease fell a dramatic 26.4 percent between 1999 and 2005.

Medicines now in the research pipeline include 36 for high blood pressure, 33 for heart failure, 16 for heart attacks, and 22 for stroke. Many of the potential medicines use cutting-edge technologies and new approaches such as one that uses human stem cells to form new heart muscle and restore cardiac functioning, and another that is a gene therapy that uses a patient's own cells to treat heart failure.

"Pharmaceutical and biotechnology researchers are making exciting progress, but it is wasted if medicines don't get to the patients who need them," says Billy Tauzin, PhRMA's president and CEO. "That is particularly true in these hard economic times with people losing their jobs and health insurance."

Help is available to patients in need through the Partnership for Prescription Assistance (PPA). A clearinghouse for more than 475 patient assistance programs, PPA is sponsored by America's pharmaceutical research companies and has helped more than 5.6 million patients nationwide, including more than 205,475 people in Indiana (contact 1-888-4PPA-NOW or

To read the Medicines in Development for Heart Disease and Stroke 2009 on the PhRMA web site, click on the following link:

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the dangers of imported drugs, visit:

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
2. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
3. New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
4. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
5. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
6. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
7. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
8. Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
9. MannKind Reports Successful Completion of Device Bioequivalence Trial
10. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
11. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... specializing in both surgical and non-surgical treatments, announced the expansion of his private ... Plastic Surgery. , Highly trained and nationally recognized for his natural approach, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
Breaking Medicine News(10 mins):